Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
embecta
Embecta stock gets a boost on Q3 beats, patch pump program remains on track
Embecta (Nasdaq:EMBC) shares rose significantly today on third-quarter results that came in well ahead of the consensus forecast. Shares of EMBC ticked up 14% to $16.39 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose slightly. It’s the second recent boost for Embecta’s […]
GenPact partners with Embecta to support diabetes market efforts
Genpact announced today that it teamed up with Embecta (Nasdaq:EMBC) to support the company in the diabetes technology market. The company says it has been working with Embecta to support its spinoff from BD and subsequent evolution as a company. “From the beginning, our relationship was rooted in shared values and a commitment to mutual […]
Embecta stock rises on reports that it might look to sell
Financial Times reports that Embecta (Nasdaq:EMBC), the former diabetes unit at BD, hired advisers to look into a possible sale of the company. Shares of EMBC ticked up 16.5% to $15.34 apiece in early-morning trading today. The company has operated as a standalone, publicly-traded company since April 2022, when it completed its spin-off from BD. […]
The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions
The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]
Embecta data highlights potential of insulin patch pumps for type 2 diabetes
Embecta (Nasdaq:EMBC) today shared new data highlighting the potential of an insulin patch pump in managing type 2 diabetes. Parsippany, New Jersey-based Embecta presented two abstracts at the American Diabetes Association Scientific Sessions in Orlando, Florida. The data pointed to the potential for adults with type 2 diabetes to better manage insulin delivery through a […]
Embecta stock skyrockets on Q1 beats, increased guidance as insulin pump tech progresses
Embecta (Nasdaq:EMBC) shares got a massive boost today on first-quarter results that came in well ahead of the consensus forecast. Shares of EMBC rose nearly 40% to $14.17 apiece in late-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.7%. The Parsippany-based BD diabetes […]
These diabetes devices are set to launch in 2024
The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year. Some of those stories didn’t end in 2023, though, as a few […]
Embecta beats The Street in Q1, raises guidance as insulin pump development moves along
Embecta (Nasdaq:EMBC) shares took a hit this morning despite Street-beating first-quarter results and increased 2024 guidance. Shares of EMBC fell 7.8% at $16.37 apiece as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — opened today relatively even. The Parsippany, New Jersey-based BD Diabetes […]
Embecta submits insulin patch pump for FDA clearance
Embecta (Nasdaq:EMBC) announced today that it submitted a 510(k) premarket filing to the FDA for its proprietary insulin patch pump. The Parsippany, New Jersey-based BD Diabetes spinoff developed a proprietary, disposable pump for people with type 2 diabetes. The company provided analysts with some details on the makeup of the open-loop system earlier this year. It […]
